| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
CDK9
CDK9 inhibitor HH1 targets cyclin-dependent kinase 9 (CDK9). CDK9 is a key regulator of transcription elongation, particularly for genes involved in cell proliferation and survival. By inhibiting CDK9, the compound blocks transcription and reduces the expression of anti-apoptotic proteins. The compound is a potent and highly selective CDK9 inhibitor. It inhibits CDK transcription. |
|---|---|
| ln Vitro |
In cell-free biochemical assays, CDK9 inhibitor HH1 inhibits CDK9 kinase activity. The compound's inhibition of CDK9 can be assessed using in vitro kinase assays with purified CDK9-cyclin T complex. The compound's selectivity for CDK9 over other CDKs can be assessed using kinase profiling assays. The compound is an inhibitor of the human CDK2-cyclin A2 complex with an IC50 value of 2 μM.
|
| ln Vivo |
In cell-based assays, CDK9 inhibitor HH1 inhibits CDK9 activity, leading to the inhibition of transcription and reduced expression of anti-apoptotic proteins. The compound's effects are evaluated in cancer cell lines, particularly hematological malignancies. By inhibiting CDK9, the compound induces apoptosis in cancer cells. The compound can be used in cancer research.
|
| Enzyme Assay |
The cell-free assay for CDK9 inhibition involves measuring the kinase activity of purified CDK9-cyclin T complex in the presence of the compound. The assay uses a peptide substrate and ATP, and the phosphorylation of the substrate is measured using radioactivity, fluorescence, or luminescence. The IC50 is determined from dose-response curves. The compound's selectivity for CDK9 can be assessed by testing against other CDKs.
|
| Cell Assay |
Cell-based assays for CDK9 inhibitor HH1 involve culturing cancer cell lines, particularly hematological malignancies, and treating them with the compound at concentrations ranging from 0.01 to 10 μM. Cells are incubated for 24-72 hours, and cell viability is assessed using MTT or CCK-8 assays. The compound's effects on transcription are assessed by measuring the expression of CDK9 target genes by qRT-PCR. Apoptosis is evaluated by Annexin V staining or caspase activity assays.
|
| Animal Protocol |
In animal models, CDK9 inhibitor HH1 has been evaluated for its anti-tumor activity in models of hematological malignancies and other cancers. Typical studies involve administration of the compound to tumor-bearing mice via intraperitoneal or oral routes. Tumor volumes are measured, and tissues are collected for analysis of CDK9 inhibition, transcription inhibition, and apoptosis. Efficacy is assessed by tumor growth inhibition.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of CDK9 inhibitor HH1 have not been extensively reported. As a small molecule with a molecular weight of 261.34 g/mol, the compound would be expected to have moderate oral bioavailability and tissue penetration. The compound is typically stored as powder at -20°C for 3 years or in solvent at -80°C for 6 months. Further pharmacokinetic studies would be required.
|
| Toxicity/Toxicokinetics |
CDK9 inhibitor HH1 is intended for research use only and lacks established toxicity profiles for therapeutic applications. Standard laboratory safety precautions should be observed when handling this chemical reagent. As a CDK9 inhibitor, the compound may have effects on normal cells as well as cancer cells. Standard toxicity studies in rodents would be required to determine the safety profile.
|
| References | |
| Additional Infomation |
CDK9 inhibitor HH1 is a research-grade compound supplied for cancer research. It is not an approved pharmaceutical and has no clinical trial history. The compound is a potent and highly selective CDK9 inhibitor. It inhibits CDK transcription and can be used in cancer research. This product is intended for research use only.
|
| Molecular Formula |
C13H15N3OS
|
|---|---|
| Molecular Weight |
261.34
|
| Exact Mass |
261.093
|
| CAS # |
204188-41-0
|
| PubChem CID |
15323467
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
453.4±55.0 °C at 760 mmHg
|
| Flash Point |
228.0±31.5 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.657
|
| LogP |
1.73
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
18
|
| Complexity |
292
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)NC1=NC(=C(S1)C(=O)C2=CC=CC=C2)N
|
| InChi Key |
WHJIFFVMTRXENN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H15N3OS/c1-8(2)15-13-16-12(14)11(18-13)10(17)9-6-4-3-5-7-9/h3-8H,14H2,1-2H3,(H,15,16)
|
| Chemical Name |
[4-amino-2-(propan-2-ylamino)-1,3-thiazol-5-yl]-phenylmethanone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~191.3 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (4.78 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (4.78 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8264 mL | 19.1322 mL | 38.2643 mL | |
| 5 mM | 0.7653 mL | 3.8264 mL | 7.6529 mL | |
| 10 mM | 0.3826 mL | 1.9132 mL | 3.8264 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
